Pharmacological evaluation of an ex vivo cervicovaginal HIV prevention model
Journal of Antimicrobial Chemotherapy · 2026
DOI: 10.1093/jac/dkag103 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Lindsey B Collins und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota Twin Cities, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Cervix Uteri, HIV Infections, Anti-HIV Agents, Vagina. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIAID NIH HHS, University of Minnesota.
Abstract (Originalsprache)
Background
The female genital tract (FGT) is a unique compartment with physiologically distinct properties complicating the extrapolation of drug efficacy; critical gaps remain in understanding regional variability within the FGT itself. We performed an in-depth investigation across endo- and ectocervical tissues on the utility of the cervical explant model to evaluate pre-exposure prophylaxis (PrEP) efficacy.
Methods
Using normal cervical tissues, we evaluated gene expression of relevant drug metabolizing enzymes and transporters (DMETs) via qRT-PCR and compared ecto- and endocervix. To determine differences in drug phosphorylation and to assess antiretroviral (ARV) efficacy, we incubated explants in tenofovir and emtricitabine then measured intracellular metabolites. Viral infectivity and dose–response with ARVs was measured using viral RNA and p24 following HIV-1JR-CSF challenge.
Results
ABCC4 expression was 3-fold lower in ectocervical tissues compared with endocervical, whereas CYP3A5 was 2-fold higher. IL-6 was correlated with ABCB1 (r = 0.52, P = 0.01) and ABCG2 (r = 0.56, P =0.005). Dose-normalized phosphorylation did not differ between endo- and ectocervix (P > 0.5). Infectivity of explants was low (53%) but did not differ by compartment. Intracellular tenofovir diphosphate concentrations were associated with a decrease in ectocervical viral replication (r =0.39, P < 0.05). There was a strong relationship between the proportion of explants infected and emtricitabine dose (P =0.02) but no relationship between intracellular emtricitabine triphosphate and protection.
Conclusions
We identified differences in DMET expression and ARV metabolism between ecto- and endocervical tissues, as well as correlations between DMET and IL-6. Ectocervical explants demonstrated consistent viral infectivity and dose-dependent inhibition. The model is useful in determining tenofovir diphosphate targets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota Twin Cities, Minneapolis, Minnesota, USA.
ORCID-Profile: Melanie R Nicol
Förderung
- NIH HHS
- NIAID NIH HHS
- University of Minnesota
- NIH
- Clinical & Translational Sciences
- UMN
- Center for Women's Health Research
- National Institutes of Health
Zitieren
APA
Collins, L. B., Le, A., & Nicol, M. R. (2026). Pharmacological evaluation of an ex vivo cervicovaginal HIV prevention model. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkag103
Vancouver
Collins LB, Le A, Nicol MR. Pharmacological evaluation of an ex vivo cervicovaginal HIV prevention model. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkag103
BibTeX
@article{Collins2026,
author = {Collins, Lindsey B and Le, An and Nicol, Melanie R},
title = {Pharmacological evaluation of an ex vivo cervicovaginal HIV prevention model},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
doi = {10.1093/jac/dkag103}
}
EUVIMED